Concepts (237)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 24 | 2020 | 401 | 3.280 |
Why?
|
| Daptomycin | 9 | 2013 | 13 | 1.710 |
Why?
|
| Staphylococcal Infections | 6 | 2018 | 176 | 1.320 |
Why?
|
| Prosthesis-Related Infections | 7 | 2020 | 215 | 1.180 |
Why?
|
| Cross Infection | 5 | 2023 | 304 | 1.060 |
Why?
|
| Anti-Infective Agents | 10 | 2005 | 63 | 0.960 |
Why?
|
| Gram-Positive Bacterial Infections | 5 | 2013 | 58 | 0.930 |
Why?
|
| Clostridium Infections | 1 | 2023 | 19 | 0.890 |
Why?
|
| Communicable Diseases | 1 | 2023 | 24 | 0.890 |
Why?
|
| Bacterial Infections | 5 | 2011 | 66 | 0.890 |
Why?
|
| Staphylococcus aureus | 7 | 2018 | 85 | 0.810 |
Why?
|
| Infection Control | 3 | 2018 | 174 | 0.770 |
Why?
|
| Catheterization, Central Venous | 2 | 2011 | 42 | 0.680 |
Why?
|
| Fluoroquinolones | 7 | 2011 | 25 | 0.640 |
Why?
|
| Skin Diseases, Bacterial | 3 | 2018 | 5 | 0.640 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 98 | 0.630 |
Why?
|
| Sepsis | 3 | 2011 | 147 | 0.630 |
Why?
|
| Bacteria | 4 | 2011 | 76 | 0.620 |
Why?
|
| Soft Tissue Infections | 3 | 2018 | 28 | 0.620 |
Why?
|
| Bacteremia | 2 | 2010 | 117 | 0.590 |
Why?
|
| Enterococcus | 4 | 2013 | 57 | 0.570 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2016 | 124 | 0.540 |
Why?
|
| Humans | 50 | 2023 | 29845 | 0.530 |
Why?
|
| Arthroplasty, Replacement | 1 | 2017 | 149 | 0.510 |
Why?
|
| Endocarditis, Bacterial | 2 | 2006 | 10 | 0.450 |
Why?
|
| Microbial Sensitivity Tests | 12 | 2018 | 110 | 0.440 |
Why?
|
| Oxazolidinones | 2 | 2010 | 6 | 0.440 |
Why?
|
| Acetamides | 2 | 2010 | 7 | 0.440 |
Why?
|
| Vancomycin Resistance | 2 | 2010 | 29 | 0.430 |
Why?
|
| Quinolones | 5 | 1991 | 22 | 0.380 |
Why?
|
| Methicillin Resistance | 2 | 2008 | 31 | 0.370 |
Why?
|
| Retrospective Studies | 11 | 2023 | 3324 | 0.340 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2016 | 37 | 0.330 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 26 | 0.310 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2019 | 16 | 0.310 |
Why?
|
| Hospitals, University | 1 | 2008 | 40 | 0.310 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 149 | 0.310 |
Why?
|
| Benchmarking | 1 | 2008 | 42 | 0.310 |
Why?
|
| Pneumonia, Bacterial | 2 | 2005 | 10 | 0.300 |
Why?
|
| Quality of Health Care | 2 | 2011 | 138 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 193 | 0.290 |
Why?
|
| Cefazolin | 2 | 2018 | 5 | 0.290 |
Why?
|
| Chlamydia trachomatis | 4 | 1991 | 17 | 0.280 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2007 | 24 | 0.280 |
Why?
|
| United States | 6 | 2017 | 2346 | 0.260 |
Why?
|
| Bone Diseases | 1 | 2005 | 24 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2020 | 696 | 0.260 |
Why?
|
| Microbiological Techniques | 2 | 2016 | 9 | 0.260 |
Why?
|
| Critical Care | 1 | 2008 | 242 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2020 | 857 | 0.250 |
Why?
|
| Ambulatory Care | 1 | 2005 | 78 | 0.250 |
Why?
|
| Infection Control Practitioners | 1 | 2004 | 2 | 0.240 |
Why?
|
| Joint Diseases | 1 | 2005 | 111 | 0.240 |
Why?
|
| Equipment Contamination | 1 | 2004 | 26 | 0.240 |
Why?
|
| Ambulatory Care Facilities | 1 | 2004 | 37 | 0.230 |
Why?
|
| Knee Prosthesis | 2 | 2020 | 244 | 0.220 |
Why?
|
| Hospitals | 1 | 2023 | 157 | 0.210 |
Why?
|
| Treatment Outcome | 10 | 2015 | 3560 | 0.210 |
Why?
|
| Hip Prosthesis | 3 | 2020 | 569 | 0.190 |
Why?
|
| Disease Management | 2 | 2019 | 122 | 0.190 |
Why?
|
| Adult | 13 | 2018 | 8746 | 0.180 |
Why?
|
| Cephalosporins | 3 | 1997 | 17 | 0.180 |
Why?
|
| Orthopedic Fixation Devices | 1 | 1999 | 24 | 0.180 |
Why?
|
| Male | 17 | 2020 | 15868 | 0.170 |
Why?
|
| Heart Valve Prosthesis | 1 | 1999 | 21 | 0.170 |
Why?
|
| Discitis | 1 | 2019 | 4 | 0.170 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 30 | 0.170 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2011 | 52 | 0.160 |
Why?
|
| Genes, Bacterial | 1 | 2018 | 6 | 0.160 |
Why?
|
| Middle Aged | 12 | 2020 | 9960 | 0.160 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 13 | 0.160 |
Why?
|
| Linezolid | 2 | 2010 | 6 | 0.160 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2018 | 38 | 0.160 |
Why?
|
| Carrier State | 1 | 2018 | 52 | 0.160 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2018 | 4 | 0.160 |
Why?
|
| Reoperation | 2 | 2020 | 927 | 0.150 |
Why?
|
| Aged | 10 | 2020 | 9619 | 0.150 |
Why?
|
| Meningitis, Bacterial | 1 | 1996 | 8 | 0.140 |
Why?
|
| Mass Screening | 1 | 2018 | 180 | 0.140 |
Why?
|
| Legionella pneumophila | 1 | 1996 | 1 | 0.140 |
Why?
|
| Clarithromycin | 1 | 1996 | 5 | 0.140 |
Why?
|
| Erythromycin | 1 | 1996 | 10 | 0.140 |
Why?
|
| Azithromycin | 1 | 1996 | 4 | 0.140 |
Why?
|
| Prosthesis Failure | 1 | 2020 | 530 | 0.140 |
Why?
|
| Female | 13 | 2020 | 16426 | 0.130 |
Why?
|
| Chicago | 4 | 2018 | 866 | 0.130 |
Why?
|
| Oxacillin | 1 | 2015 | 2 | 0.130 |
Why?
|
| Arthroplasty | 1 | 2016 | 138 | 0.130 |
Why?
|
| Methicillin | 1 | 2015 | 6 | 0.130 |
Why?
|
| Drug Hypersensitivity | 1 | 1995 | 16 | 0.130 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 2 | 1991 | 3 | 0.130 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 4930 | 0.130 |
Why?
|
| Diarrhea | 3 | 1990 | 47 | 0.130 |
Why?
|
| Ceftizoxime | 1 | 1994 | 2 | 0.120 |
Why?
|
| Neisseria gonorrhoeae | 2 | 1991 | 7 | 0.120 |
Why?
|
| Cyclic N-Oxides | 1 | 1993 | 5 | 0.110 |
Why?
|
| Campylobacter | 1 | 1993 | 8 | 0.110 |
Why?
|
| Endocarditis | 1 | 2013 | 9 | 0.110 |
Why?
|
| Quinoxalines | 1 | 1993 | 11 | 0.110 |
Why?
|
| Enterococcus faecalis | 1 | 2013 | 7 | 0.110 |
Why?
|
| Enterococcus faecium | 1 | 2013 | 15 | 0.110 |
Why?
|
| Drainage | 1 | 2013 | 50 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2015 | 1953 | 0.100 |
Why?
|
| Uterine Cervicitis | 1 | 1991 | 2 | 0.100 |
Why?
|
| Urethritis | 1 | 1991 | 2 | 0.100 |
Why?
|
| Aza Compounds | 1 | 2011 | 1 | 0.100 |
Why?
|
| Administration, Ophthalmic | 1 | 2011 | 1 | 0.100 |
Why?
|
| Azepines | 1 | 2011 | 7 | 0.100 |
Why?
|
| Quinolines | 1 | 2011 | 16 | 0.100 |
Why?
|
| 4-Quinolones | 4 | 1995 | 6 | 0.100 |
Why?
|
| Serratia marcescens | 1 | 2010 | 11 | 0.090 |
Why?
|
| Serratia Infections | 1 | 2010 | 10 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 55 | 0.090 |
Why?
|
| Naphthyridines | 1 | 1990 | 6 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 143 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2011 | 70 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 98 | 0.090 |
Why?
|
| Illinois | 1 | 2011 | 241 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 89 | 0.090 |
Why?
|
| Models, Biological | 1 | 2011 | 347 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 332 | 0.090 |
Why?
|
| Tetracyclines | 1 | 1989 | 3 | 0.090 |
Why?
|
| Rifampin | 1 | 1989 | 7 | 0.080 |
Why?
|
| Drug Resistance, Microbial | 3 | 1996 | 96 | 0.080 |
Why?
|
| Minocycline | 1 | 1989 | 8 | 0.080 |
Why?
|
| Shock, Septic | 1 | 1989 | 62 | 0.080 |
Why?
|
| Time Factors | 4 | 2020 | 1641 | 0.080 |
Why?
|
| Neurocognitive Disorders | 1 | 1988 | 19 | 0.080 |
Why?
|
| Algorithms | 1 | 2010 | 401 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 92 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2008 | 67 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2008 | 39 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2007 | 17 | 0.080 |
Why?
|
| Vancomycin | 1 | 2008 | 58 | 0.080 |
Why?
|
| Skin Diseases, Infectious | 1 | 2007 | 9 | 0.080 |
Why?
|
| Prognosis | 1 | 2010 | 874 | 0.070 |
Why?
|
| Q Fever | 1 | 2006 | 4 | 0.070 |
Why?
|
| Travel | 1 | 2006 | 14 | 0.070 |
Why?
|
| Community-Acquired Infections | 2 | 2005 | 78 | 0.070 |
Why?
|
| Registries | 1 | 2007 | 191 | 0.070 |
Why?
|
| Tobramycin | 1 | 2005 | 10 | 0.070 |
Why?
|
| Calcium Sulfate | 1 | 2005 | 20 | 0.060 |
Why?
|
| Bone Substitutes | 1 | 2005 | 26 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2011 | 456 | 0.060 |
Why?
|
| Animals | 2 | 2011 | 4639 | 0.060 |
Why?
|
| Humerus | 1 | 2005 | 101 | 0.060 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2004 | 5 | 0.060 |
Why?
|
| Risk Factors | 1 | 2011 | 2466 | 0.060 |
Why?
|
| Doxycycline | 3 | 2006 | 20 | 0.060 |
Why?
|
| Bone Transplantation | 1 | 2005 | 227 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 334 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2020 | 144 | 0.050 |
Why?
|
| Ciprofloxacin | 3 | 1993 | 28 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 2 | 2007 | 37 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 399 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2005 | 1857 | 0.050 |
Why?
|
| Ofloxacin | 2 | 1997 | 5 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2018 | 13 | 0.040 |
Why?
|
| Rectum | 1 | 2018 | 61 | 0.040 |
Why?
|
| Gas Gangrene | 1 | 2018 | 1 | 0.040 |
Why?
|
| Leukocidins | 1 | 2018 | 2 | 0.040 |
Why?
|
| Dermatomycoses | 1 | 2018 | 3 | 0.040 |
Why?
|
| Exotoxins | 1 | 2018 | 14 | 0.040 |
Why?
|
| Pyomyositis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2018 | 12 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 28 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 67 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2018 | 29 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 2018 | 21 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 508 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 45 | 0.040 |
Why?
|
| Prodrugs | 1 | 1997 | 4 | 0.040 |
Why?
|
| Ceftriaxone | 1 | 1997 | 5 | 0.040 |
Why?
|
| Cefuroxime | 1 | 1997 | 2 | 0.040 |
Why?
|
| Levofloxacin | 1 | 1997 | 5 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 142 | 0.040 |
Why?
|
| Prevalence | 1 | 2018 | 494 | 0.040 |
Why?
|
| Legionnaires' Disease | 1 | 1996 | 1 | 0.030 |
Why?
|
| Emergencies | 1 | 1996 | 39 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 1996 | 20 | 0.030 |
Why?
|
| Campylobacter Infections | 2 | 1993 | 11 | 0.030 |
Why?
|
| Acute Disease | 1 | 1996 | 225 | 0.030 |
Why?
|
| Skin Tests | 1 | 1995 | 14 | 0.030 |
Why?
|
| Listeriosis | 1 | 1995 | 6 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2018 | 312 | 0.030 |
Why?
|
| Adolescent | 2 | 2018 | 2334 | 0.030 |
Why?
|
| Staphylococcus | 1 | 1995 | 10 | 0.030 |
Why?
|
| Drug Utilization | 1 | 1995 | 27 | 0.030 |
Why?
|
| Arthritis, Infectious | 1 | 1995 | 58 | 0.030 |
Why?
|
| Campylobacter coli | 1 | 1993 | 2 | 0.030 |
Why?
|
| Metronidazole | 1 | 1993 | 8 | 0.030 |
Why?
|
| Borrelia burgdorferi Group | 1 | 1993 | 6 | 0.030 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1993 | 16 | 0.030 |
Why?
|
| Contraindications | 1 | 2013 | 42 | 0.030 |
Why?
|
| Blood | 1 | 2013 | 25 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2013 | 33 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 232 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 310 | 0.030 |
Why?
|
| Osteoarthritis, Hip | 1 | 2013 | 96 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2013 | 1824 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 1969 | 0.030 |
Why?
|
| Ureaplasma urealyticum | 1 | 1991 | 1 | 0.030 |
Why?
|
| Mycoplasma | 1 | 1991 | 4 | 0.030 |
Why?
|
| Treponema pallidum | 1 | 1991 | 4 | 0.030 |
Why?
|
| Gonorrhea | 1 | 1991 | 8 | 0.030 |
Why?
|
| Serratia | 1 | 2010 | 7 | 0.020 |
Why?
|
| Syringes | 1 | 2010 | 11 | 0.020 |
Why?
|
| Blood Sedimentation | 1 | 2010 | 64 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 51 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 130 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1990 | 7 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 125 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 90 | 0.020 |
Why?
|
| Norfloxacin | 1 | 1989 | 2 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1989 | 66 | 0.020 |
Why?
|
| Hip Joint | 1 | 2013 | 357 | 0.020 |
Why?
|
| Osteoarthritis, Knee | 1 | 2013 | 382 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1989 | 32 | 0.020 |
Why?
|
| Pneumonia | 1 | 1989 | 67 | 0.020 |
Why?
|
| Knee Joint | 1 | 2013 | 800 | 0.020 |
Why?
|
| Coxiella burnetii | 1 | 2006 | 3 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2006 | 7 | 0.020 |
Why?
|
| Australia | 1 | 2006 | 46 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1126 | 0.020 |
Why?
|
| Drug Implants | 1 | 2005 | 12 | 0.020 |
Why?
|
| Osteomyelitis | 1 | 2005 | 23 | 0.020 |
Why?
|
| Dogs | 1 | 2005 | 261 | 0.020 |
Why?
|
| Radiography | 1 | 2005 | 678 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 58 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 245 | 0.010 |
Why?
|
| Macrolides | 1 | 1993 | 5 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1995 | 126 | 0.010 |
Why?
|
| Dysentery, Bacillary | 1 | 1990 | 2 | 0.010 |
Why?
|
| Campylobacter fetus | 1 | 1990 | 4 | 0.010 |
Why?
|
| Salmonella Infections | 1 | 1990 | 3 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1990 | 522 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 349 | 0.000 |
Why?
|